Q-omics provides the consensus-scored RHEB profile across patient tissues and cancer cell-line models. RHEB expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RHEB is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RHEB RNA expression shows 19,185 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where RHEB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHEB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHEB survival associations across molecular data types. RHEB RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHEB RNA expression–survival associations across cancer types. High RHEB expression shows unfavorable associations in KIRP, UVM, ACC, CESC, PAAD and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RHEB RNA expression.
This table summarizes RHEB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RHEB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHEB shows higher tumor expression in HNSC, KIRP, LIHC, COAD, LUAD and BRCA. The HNSC box plot shows higher RHEB RNA expression in tumor versus normal tissue (log2 FC = +0.941, t-test p < 0.001).
This table shows molecular features associated with RHEB in patient tissues and cancer cell lines. In patient samples, RHEB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHEB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
